Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer

Por Umekita, Yoshihisa, Ohi, Yasuyo, Souda, Masakazu, Rai, Yoshiaki, Sagara, Yoshiaki, Sagara, Yasuaki, Tamada, Shugo, Tanimoto, Akihide
Publicado em 2011

Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

Por Shiroiwa, Takeru, Fukuda, Takashi, Shimozuma, Kojiro, Mouri, Mitsuko, Hagiwara, Yasuhiro, Kawahara, Takuya, Ohsumi, Shozo, Hozumi, Yasuo, Sagara, Yoshiaki, Ohashi, Yasuo, Mukai, Hirofumi
Publicado no BMC Cancer (2017)

Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies

Por Hida, Akira I., Sagara, Yasuaki, Yotsumoto, Daisuke, Kanemitsu, Shuichi, Kawano, Junko, Baba, Shinichi, Rai, Yoshiaki, Oshiro, Yumi, Aogi, Kenjiro, Sagara, Yoshiaki, Ohi, Yasuyo
Publicado no Breast Cancer Res Treat (2016)

Mucocele-like lesions of the breast: a long-term follow-up study

Por Ohi, Yasuyo, Umekita, Yoshihisa, Rai, Yoshiaki, Sagara, Yasuaki, Baba, Shinichi, Tamada, Shugo, Sagara, Yoshiaki, Kukita, Taeko, Yoshioka, Takako, Hatanaka, Kazuhito, Sagara, Yoshiatsu, Tanimoto, Akihide
Publicado em 2011